Ozempic® and Wegovy® show up in the same conversations so often that it's easy to assume they're basically the same drug marketed two different ways. They do share an active ingredient, and both are made by Novo Nordisk, but the FDA evaluated and approved them separately, for separate uses, with separate labels. That distinction is not just a technicality: it affects what each product's dosing schedule looks like, what each one's safety data actually covers, and what it means when either medication is used outside its approved purpose.
This article walks through what the two products have in common, where their FDA approvals and labeled doses diverge, what "off-label" use means in this context, and how a clinician typically approaches a conversation about either option. None of this is a substitute for an individualized medical evaluation.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation with a licensed clinician.
Same active ingredient, different products
Both Ozempic® and Wegovy® contain semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Semaglutide mimics a naturally occurring gut hormone that slows digestion, signals the pancreas to release insulin when blood sugar rises, and acts on appetite centers in the brain to increase feelings of fullness. That shared mechanism is why the two products are so often discussed together.
Despite the shared molecule, Ozempic® and Wegovy® are not interchangeable brand names for one product. Each went through its own FDA review process, carries its own prescribing label, and comes in its own pen presentation with its own dosing schedule. They are, in FDA terms, two distinct approved drug products that happen to be built on the same active ingredient.
This is a pattern that shows up elsewhere in the GLP-1 category too. Tirzepatide, the active ingredient in Mounjaro® and Zepbound™, follows a similar split: one brand approved for type 2 diabetes, another approved for chronic weight management. If you want a deeper look at how semaglutide compares with that other molecule, see our article on semaglutide vs. tirzepatide.
FDA-approved uses for each
Ozempic® is FDA-approved for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise, and it is also approved to reduce the risk of certain major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes who also have established heart disease. Its label is built around diabetes management, with cardiovascular risk reduction as a second approved use in that same patient population.
Wegovy® is FDA-approved for chronic weight management in adults, and in some adolescents, with obesity, or who are overweight and have at least one weight-related medical condition, used together with a reduced-calorie diet and increased physical activity. It was studied in a different population with a different primary goal: sustained weight management rather than glycemic control.
The two labels overlap in the sense that both involve semaglutide and both can affect body weight. But they were approved to treat different conditions, in trials designed around different endpoints, which is exactly why they exist as two separate products instead of one.
| Ozempic® | Wegovy® | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Primary FDA-approved use | Type 2 diabetes; reducing certain cardiovascular risks in adults with type 2 diabetes and heart disease | Chronic weight management in adults with obesity or overweight plus a weight-related condition |
| Maximum labeled weekly dose | 2 mg | 2.4 mg |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Compounded availability | Not applicable to the brand; compounded semaglutide exists separately and is not FDA-approved | Not applicable to the brand; compounded semaglutide exists separately and is not FDA-approved |
How the maximum doses differ
Ozempic®'s label caps the maintenance dose at 2 mg once weekly, reached through a gradual step-up schedule that typically starts at a much lower dose and increases every four weeks as tolerated. Wegovy®'s label allows for a higher maximum of 2.4 mg once weekly, following its own separate, slightly longer titration schedule.
That 0.4 mg gap is not an arbitrary marketing difference. Each maximum dose reflects what was actually studied in that product's clinical trial program for its approved use. Wegovy®'s trials, built around chronic weight management as the primary goal, evaluated doses up to 2.4 mg; Ozempic®'s trials, built around blood sugar control, evaluated doses up to 2 mg. The dose on the label is the dose the FDA found to have an acceptable balance of benefit and risk for that specific approved purpose, in that specific trial population, not a one-size-fits-all number.
In both cases, gradual titration exists to let the digestive system adjust and to reduce the intensity of gastrointestinal side effects, which are the most commonly reported side effects of either product. Jumping straight to a higher dose, or exceeding what's on either label, isn't how either medication is intended to be used, and it is not something a licensed clinician would do without individualized justification.
Off-label use and why it matters
Because Ozempic® and Wegovy® share the same active ingredient, some clinicians have historically prescribed Ozempic® for weight management in patients without type 2 diabetes. That is an off-label use: prescribing an FDA-approved drug for a purpose other than what it's officially approved for. Off-label prescribing is legal and happens across medicine, but it means the safety and effectiveness data specific to that particular use, in that particular product, wasn't the basis of the FDA's approval for that product.
Off-label use matters here for a practical reason: Ozempic® and Wegovy® have separate labels, separate warnings sections, and separate recommended dosing schedules, even though they share a molecule. A clinician weighing an off-label approach has to reason from a different evidence base than the one the product's own label was built on, which is one reason many prescribers now default to the product actually approved for the goal in question when that option is appropriate and accessible.
Compounded semaglutide is a separate topic from either brand product. Compounded medications, including compounded semaglutide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate, such as during an FDA-declared shortage or to meet a specific patient need. You can read more in our article on what compounded semaglutide is, and in our comparison of compounded semaglutide vs. Wegovy®.
FDA-approved brand products, including Ozempic®, Wegovy®, Mounjaro®, and Zepbound™, are evaluated by the FDA for safety, effectiveness, and manufacturing quality before they reach the market. Compounded versions of semaglutide or tirzepatide have not gone through that same FDA review process, and the difference between "FDA-approved" and "compounded" is not a difference of degree, it's a difference in regulatory status that's worth understanding before any treatment decision.
How to talk to a clinician about options
If you're trying to figure out which of these conversations applies to you, it helps to start with your actual goal. If blood sugar control is the primary concern, particularly alongside type 2 diabetes and cardiovascular risk, that's the territory Ozempic® was studied and approved for. If chronic weight management is the primary goal, Wegovy® was studied and approved specifically for that. Naming your goal clearly during an evaluation helps a clinician match it to the product whose approval and trial data actually address it.
It's also worth raising practical questions directly: whether your insurance covers one product over the other, whether a specific dose or titration pace fits your history, and whether you have any conditions, such as a personal or family history of certain thyroid cancers, that a clinician needs to weigh before prescribing either one. These are reasonable topics for a consultation, not things to research and decide on your own beforehand.
An online evaluation does not guarantee that Ozempic®, Wegovy®, or any other medication will be prescribed. An independent licensed clinician reviews your health history and determines what, if anything, is clinically appropriate, and that decision is made individually rather than by simply requesting a particular brand name.
The bottom line
Ozempic® and Wegovy® share an active ingredient, semaglutide, and a manufacturer, but they are separately approved products with different labeled uses, different maximum doses, and different clinical trial foundations behind those numbers. Ozempic® is approved for type 2 diabetes and certain cardiovascular risk reduction; Wegovy® is approved for chronic weight management. Using either outside its approved use is possible but is an off-label decision that belongs to a licensed clinician, not a patient acting alone.
You can find more on related topics in our Weight Management section, including how semaglutide compares with tirzepatide and what to know about side effects of GLP-1 medications.
Important Safety Information
Indication. Ozempic® (semaglutide) is FDA-approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease. Wegovy® (semaglutide) is FDA-approved for chronic weight management in adults, and in some adolescents, with obesity or who are overweight with a weight-related condition, used with a reduced-calorie diet and increased physical activity. Compounded semaglutide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality; it may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects of semaglutide, across both products, are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These are often mild and tend to ease over time, especially as the dose is increased gradually.
Warnings. Both products carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about any history of pancreatitis, diabetic retinopathy, gallbladder disease, or kidney problems, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Is Wegovy® just a stronger dose of Ozempic®?
Not exactly. Both contain the same active ingredient, semaglutide, but they are separately FDA-approved products with different labeled uses, different dosing schedules, and different maximum doses. Wegovy®'s higher maximum dose was studied specifically for chronic weight management, while Ozempic®'s dosing was studied for type 2 diabetes.
Can a clinician prescribe Ozempic® for weight loss instead of Wegovy®?
Prescribing Ozempic® specifically for weight management, rather than for its approved use in type 2 diabetes, would be an off-label use, and whether that is appropriate is a decision for a licensed clinician based on an individual evaluation. An online consultation does not guarantee that either medication will be prescribed.
Why does Wegovy® have a higher maximum dose than Ozempic®?
The two products were evaluated in separate clinical trial programs for separate approved uses, and the dosing in each label reflects what was studied for that specific indication. Wegovy®'s clinical trials for chronic weight management used doses up to 2.4 mg weekly, while Ozempic®'s trials for type 2 diabetes topped out at 2 mg weekly.
Are compounded semaglutide products the same as Ozempic® or Wegovy®?
They contain the same active molecule, but compounded semaglutide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality, unlike the FDA-approved brand products. Compounded medications may be prescribed by an independent licensed physician when clinically appropriate, such as during a supply shortage.
How does a clinician decide which option, if any, is right for me?
A prescribing clinician considers your overall health history, whether you have type 2 diabetes or a weight-related condition, current medications, and your personal goals. That evaluation determines whether Ozempic®, Wegovy®, a compounded option, or no GLP-1 medication at all is appropriate; it is not a choice a patient makes unilaterally by requesting a specific brand.
